Research using Saskatchewan Health Data Shows Impact of DMTs for MS Patients
Utilizing health administrative data from Saskatchewan between 1997 to 2016, researchers at the University of Saskatchewan and University of Manitoba studied the impacts of disease-modifying therapy (DMT) usage for people with MS on overall healthcare use.
The study's findings suggest that while the use of DMTs for MS is a costly form of treatment, in the long run this initial investment pays off. Disease-modifying therapies reduce the overall cost of treatment and care in healthcare institutions for people who live with MS.
This recent research was funded in part by the great folks at the Saskatchewan Health Research Foundation.